Out today in @science.org! What if you could chart cells' regulatory programs at unprecedented resolution? In my work with Jorge Martin-Rufino from the @bloodgenes.bsky.social lab, we dissect the genome’s control circuits and find where key genetic variation hides bit.ly/3YhBMoO

Transcription factor networks disproportionately enrich for heritability of blood cell phenotypes

Most phenotype-associated genetic variants map to noncoding regulatory regions of the human genome, but their mechanisms remain elusive in most cases. We developed a highly efficient strategy, Perturb...

bit.ly

A huge congrats to @dpastoors.bsky.social and @delwelruud.bsky.social for this fantastic work!

Dorien Pastoors@dpastoors.bsky.social · 2y ago

Excited to share our preprint on #HemeSky: "MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia"! @delwelruud.bsky.social and co-authors! www.biorxiv.org/content/10.1... [1/15]

Congrats @tjflemin.bsky.social, @bloodgenes.bsky.social and coauthors! I feel like preprint directly ties together #HemeSky 's favorite two transcription factors: MECOM and CEBPA. As to why these two: I'm heavily biased as our complementary work will also be on biorxiv soon (monday!!)

Travis Fleming@tjflemin.bsky.social · 2y ago

Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇 www.biorxiv.org/content/10.1...

Wonderful to have this work led by @tjflemin.bsky.social along with other colleagues in our laboratory, as well as great collaborators, out on @biorxivpreprint.bsky.social! Stay tuned for exciting complementary work from @dpastoors.bsky.social, Ruud Delwel, and co coming soon!

Travis Fleming@tjflemin.bsky.social · 2y ago

Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇 www.biorxiv.org/content/10.1...

Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇 www.biorxiv.org/content/10.1...

🙏 🙏 Honored to have the work from @tjflemin.bsky.social from our lab featured in the Best of #ASH24!!!

Mike Fernandez@mikemfernandez.bsky.social · 2y ago

Huge congratulations to both @tjflemin.bsky.social and @bloodgenes.bsky.social! Both Outstanding Abstract Achievement Award and Best of ASH! #ASH24 #ASHKudos @ash-hematology.bsky.social

Had a blast presenting our work today at #ASH24! Very grateful for my mentors and colleagues for their support. Stay tuned very soon for more on this study on how we’ve functionally dissected high-risk leukemias

Vijay G. Sankaran@bloodgenes.bsky.social · 2y ago

Outstanding presentation at #ASH24 from @tjflemin.bsky.social from our lab, where he discussed his work on the mechanisms by which MECOM drives high-risk AMLs!!! Congratulations, Travis!!!

Please come see @tjflemin.bsky.social present on his groundbreaking work at @ash-hematology.bsky.social #ASH24 that reveals a surprisingly simple regulatory logic for high-risk AMLs ... Happening soon in Manchester Grand Hyatt San Diego Seaport Ballrooms ABCD: ash.confex.com/ash/2024/web...

#ASH24 Please check out these two abstracts from our laboratory! Travis Fleming will present his talk this afternoon and Alexis Caulier will present his poster this evening!

Anticipating a hefty hangover from those hot Miami Nights at #ASH24 this weekend? Have no fear! I have the solution. Doctors hate this one trick: 🧵👇